Full Press Release Details
Blue Water Vaccines Announces Signing of Sponsored
Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated,
Orally Delivered Chlamydia Vaccine
CINCINNATI, OH, April 12 2023 -- Blue
Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company
developing transformational vaccines to address significant global health challenges, today announced the signing of a Sponsored Research
Agreement (the "Agreement") with The University of Texas Health Science Center at San Antonio ("UT Health Science Center
San Antonio") to fund a non-human primate ("NHP") study to evaluate the efficacy of BWV-401, a live attenuated, orally
delivered Chlamydia vaccine.
In November 2022, BWV signed an exclusive,
global license agreement with UT Health Science Center San Antonio for the development of this novel vaccine candidate, BWV-401, to prevent
Chlamydia infection. BWV-401 utilizes a modified strain of Chlamydia to colonize in the gastrointestinal tract and has produced transmucosal
protection against genital tract Chlamydia infection in mouse models without altering the gut microbiota. In this new effort, BWV will
fund an NHP study to further evaluate the efficacy of BWV-401 and provide additional support for development towards human clinical trials.
Often regarded as the gold standard
animal model for drug development and approval, NHP studies allow researchers to assess safety and efficacy of vaccines in human-like
models without completing full, robust human clinical trials. In this upcoming study, NHPs will be vaccinated with BWV-401 and subsequently
challenged against Chlamydia to validate the hypothesis that, along with being a safe, this vaccine, when delivered orally, is capable
of eliciting an effective immune response in the genital tract and can protect against Chlamydia infection.
"We are thrilled to initiate
this study with our partners at UT Health Science Center San Antonio for BWV-401," said Joseph Hernandez, Chairman and Chief Executive
Officer of Blue Water Vaccines. "There remains a high unmet need for an efficacious Chlamydia vaccine to prevent the millions of
infections seen around the world each year. We look forward to completing this study and moving one step closer towards clinical development
of this novel vaccine."
According to the CDC, Chlamydia is the most frequently reported bacterial
STI in the United States, with about 1.6 million new cases reported in 2020 alone. Globally, the WHO estimates about 129 million new cases
of Chlamydia each year and may be an underrepresentation given many cases are asymptomatic and low availability of diagnostic testing
in low- and middle-income countries. Currently, there is no vaccine available to prevent Chlamydia infection, and the main treatment is
through antibiotic regimens with the possibility of reinfection after antibiotics have treated the disease. If undetected or left untreated,
Chlamydia represents a major cause of pelvic inflammatory disease and infertility in women.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on
developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the Company holds
the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, St. Jude
Children's Hospital, and The University of Texas Health Science Center at San Antonio. The Company is developing a universal flu
vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile
virus-like particle (VLP) vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including
norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus)
vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in
children, and prevention of pneumonia in older people at risk for contracting pneumococcal pneumonia, a significant unmet medical need.
The advantage of this technology includes a serotype independent mucosal immunity that prevents colonization in the upper respiratory
tract as well as systemic immunity that can confer serotype independent against invasive pneumococcal disease. The Company is also developing
a Chlamydia vaccine candidate with UT Health Science Center San Antonio to prevent infection and reduce the need for antibiotic
treatment associated with contracting Chlamydia disease. For more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based on BWV's current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV's vaccine candidates;
the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited
research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development,
there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation
to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV's Annual Report on Form
10-K, filed with the Securities and Exchange Commission (the "SEC") on March 9, 2023 and periodic reports filed with the SEC
on or after the date thereof. All of BWV's forward-looking statements are expressly qualified by all such risk factors and other
cautionary statements. The information set forth herein speaks only as of the date thereof.
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Investor Contact Information:
Blue Water Investor Relations